Overcoming Resistance in Cancer with Chemistry

James Porter, CEO of Nuvalent, discusses how the company designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.